Loading stock data…
DMII
$10.09+0.01 (+0.10%)
Drugs Made In America Acquisition II Corp.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JPMBACGS
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$10.09
Potential Downside
81.4%
Whystock Fair Value$1.88
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or mor...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$641.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
77.46
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.75%
Volume
Today's trading volume
3,451
Recent News
NexGen Energy’s Rook I Project Emerges as a Key Source in the Next Uranium Supply Wave
MMCAP International increased its stake in NexGen Energy during the fourth quarter, deepening exposure to the company’s Rook I uranium project in Canada. As governments extend reactor lifespans and reconsider nuclear expansion, attention is turning to future uranium supply and how quickly projects like Rook I can begin production.
Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company
Key Insights Institutions' substantial holdings in Drugs Made In America Acquisition II implies that they have...